Abstract
The mono-carboxypeptidase Angiotensin-Converting Enzyme 2 (ACE2) is an important “player” of the renin-angiotensin system (RAS). ACE2 is also the receptor for SARS-CoV-2, the new coronavirus that causes COVID-19. It has been hypothesized that following SARS-CoV-2/ACE2 internalization Ang II level would increase in parallel to a decrease of Ang-(1-7) in COVID-19 patients. In this preliminary report, we analyzed the plasma levels of angiotensin peptides in 19 severe COVID-19 patients and 19 non-COVID-19 volunteers, to assess potential outcome associations. Unexpectedly, a significant increase in circulating Ang-(1-7) and lower Ang II plasma level were found in critically ill COVID-19 patients. Accordingly, an increased Ang-(1-7)/ Ang II ratio was observed in COVID-19 suggesting a RAS dysregulation toward an increased formation of Ang-(1-7) in these patients.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
RBR 35734p
Clinical Protocols
http://www.ensaiosclinicos.gov.br/rg/RBR-35734p/
Funding Statement
This work was supported by the Research Support Foundation of the State of Minas Gerais (FAPEMIG), grant number: APQ-00325-20, and Angitec. M.J.C.S., T.V.B. and R.A.S. also acknowledge the National Council for Scientific and Technological Development (CNPq) for the personal support (M.J.C.S.: #306962/2019-5; T.V.B.: # 309122/2019-8; R.A.S.: #310515/2015-7).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol has been approved by the Ethics Committee of the Federal University of Minas Gerais, Belo Horizonte, Brazil, registered in the Brazilian Registry of Clinical Trials, RBR (CAAE: 34080720.0.1001.5149; RBR-35734p)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We willing to provide the raw data upon request
